PCM
EPIX

Prelude Capital Management’s ESSA Pharma EPIX Stock Holding History

Prelude Capital Management’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,000
Closed -$44.8K – 1283
2024
Q4 		$44.8K Buy
+25,000
New +$79.6K ﹤0.01% 1150
2022
Q2 		– Sell
-20,350
Closed -$126K – 1874
2022
Q1 		$126K Hold
20,350
– – ﹤0.01% 1365
2021
Q4 		$289K Sell
20,350
-1
-0% -$11 0.01% 1342
2021
Q3 		$163K Buy
+20,351
New +$324K ﹤0.01% 1411
2021
Q1 		– Sell
-23,304
Closed -$278K – 1625
2020
Q4 		$278K Buy
23,304
+10,804
+86% +$76.1K 0.01% 950
2020
Q3 		$86K Buy
+12,500
New +$84.8K ﹤0.01% 960

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $133M AUM 42.18% 1-Year Est. Return

Prelude Capital Management's EPIX Position: Q1 2025 in Review

Prelude Capital Management sold out of ESSA Pharma (EPIX) in Q1 2025, closing a stake of 25,000 shares — an estimated $44.8K sold.

Prelude Capital Management first reported a position in EPIX in Q3 2020 and held it in 6 quarters. The position peaked at $289K in Q4 2021. 36 funds tracked by Wall St. Rank hold EPIX as of Q1 2025.

  • Prelude Capital Management reported no remaining ESSA Pharma position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 25,000 ESSA Pharma shares in Q1 2025, an estimated $44.8K.
  • Prelude Capital Management first reported a position in ESSA Pharma in Q3 2020 and held it in 6 quarters.
  • Prelude Capital Management's ESSA Pharma position peaked at $289K in Q4 2021.
  • 36 funds tracked by Wall St. Rank held ESSA Pharma as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.